198 related articles for article (PubMed ID: 15231660)
1. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease.
Barnes GL; Hebert KE; Kamal M; Javed A; Einhorn TA; Lian JB; Stein GS; Gerstenfeld LC
Cancer Res; 2004 Jul; 64(13):4506-13. PubMed ID: 15231660
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
3. A role for Runx2 in normal mammary gland and breast cancer bone metastasis.
Shore P
J Cell Biochem; 2005 Oct; 96(3):484-9. PubMed ID: 16052475
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE
Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852
[TBL] [Abstract][Full Text] [Related]
5. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.
Schwaninger R; Rentsch CA; Wetterwald A; van der Horst G; van Bezooijen RL; van der Pluijm G; Löwik CW; Ackermann K; Pyerin W; Hamdy FC; Thalmann GN; Cecchini MG
Am J Pathol; 2007 Jan; 170(1):160-75. PubMed ID: 17200191
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer-derived factors facilitate osteolytic bone metastasis.
Rose AA; Siegel PM
Bull Cancer; 2006 Sep; 93(9):931-43. PubMed ID: 16980236
[TBL] [Abstract][Full Text] [Related]
8. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast cancer induces an osteoblast inflammatory response.
Kinder M; Chislock E; Bussard KM; Shuman L; Mastro AM
Exp Cell Res; 2008 Jan; 314(1):173-83. PubMed ID: 17976581
[TBL] [Abstract][Full Text] [Related]
11. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
Zhao Y; Bachelier R; Treilleux I; Pujuguet P; Peyruchaud O; Baron R; Clément-Lacroix P; Clézardin P
Cancer Res; 2007 Jun; 67(12):5821-30. PubMed ID: 17575150
[TBL] [Abstract][Full Text] [Related]
12. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone.
Tamura D; Hiraga T; Myoui A; Yoshikawa H; Yoneda T
Int J Oncol; 2008 Jul; 33(1):17-24. PubMed ID: 18575746
[TBL] [Abstract][Full Text] [Related]
13. Osteoclasts direct bystander killing of cancer cells in vitro.
Ramnaraine M; Pan W; Clohisy DR
Bone; 2006 Jan; 38(1):4-12. PubMed ID: 16139579
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
15. Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo.
Lemieux P; Harvey J; Guise T; Dallas M; Oesterreich S; Yin Jj; Selander K; Fuqua S
J Bone Miner Res; 1999 Sep; 14(9):1570-5. PubMed ID: 10469286
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo.
Zhao Z; Zhao M; Xiao G; Franceschi RT
Mol Ther; 2005 Aug; 12(2):247-53. PubMed ID: 16043096
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of osteolytic bone metastases in breast carcinoma.
Käkönen SM; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):834-9. PubMed ID: 12548583
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant.
Carcel-Trullols J; Stanley JS; Saha R; Shaaf S; Bendre MS; Monzavi-Karbassi B; Suva LJ; Kieber-Emmons T
Int J Oncol; 2006 May; 28(5):1173-83. PubMed ID: 16596233
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
20. Increased Dickkopf-1 expression in breast cancer bone metastases.
Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
